MannKind
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine ...
Latest News
5 days ago · seekingalpha.com
MannKind's ReadyFlow Launch Keeps The Bull Case AliveMNKD's ReadyFlow could widen Furoscix's reach into more outpatient settings, which I consider a promising value driver in the long run. Also, their pediatric launch expands Afrezza's market. The main caveat to this is that it requires an added lung-function screening for patients. Aside from that, Tyvaso DPI royalties remain vital for MNKD, but fortunately, they're likely to keep growing as well in the near term.
11 days ago · seekingalpha.com
MannKind Corporation (MNKD) Q3 2026 Earnings Call TranscriptMannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript
11 days ago · marketbeat.com
MannKind Q3 Earnings Call HighlightsMannKind NASDAQ: MNKD expects to return to profitability in the fourth quarter after reporting higher third-quarter revenue and a net loss, as the company's FUROSCIX ReadyFlow and pediatric Afrezza launches gain traction.
11 days ago · zacks.com
Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key MetricsAlthough the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
11 days ago · zacks.com
MannKind (MNKD) Reports Q3 Loss, Misses Revenue EstimatesMannKind (MNKD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.03 per share a year ago.
18 days ago · globenewswire.com
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that it will report third quarter 2026 financial results after market close on Thursday, November 5, 2026.
1 month ago · globenewswire.com
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemide Consistent bioavailability, diuresis and natriuresis across injection sites support flexible administration in clinical practice Cross-study analysis demonstrates comparable diuretic and natriuretic responses between Furoscix ReadyFlow and Furoscix (furosemide) On-body Infusor, supporting a seamless transition to ReadyFlow Data presentations build on the July 2026 FDA approval and U.
2 months ago · marketbeat.com
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains MomentumMannKind NASDAQ: MNKD CFO Chris Prentiss outlined the company's commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX ReadyFlow, and Phase 1b data for MNKD-201 in idiopathic pulmonary fibrosis, or IPF.
2 months ago · globenewswire.com
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight ManagementCollaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
3 months ago · globenewswire.com
MannKind to Present at Upcoming Investor ConferencesDANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove MNKD